Literature DB >> 30338351

[Centralized molecular tumor diagnostics by commercial providers : Consequences for patients, patient care, and research].

P Schirmacher1, A Stenzinger2, T Kirchner3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30338351     DOI： 10.1007/s00292-018-0523-x

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


× No keyword cloud information.
  2 in total

1.  Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology.

Authors:  Nicole M Kuderer; Kimberly A Burton; Sibel Blau; Andrea L Rose; Stephanie Parker; Gary H Lyman; C Anthony Blau
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

2.  Myriad take two: Can genomic databases remain secret?

Authors:  Christi J Guerrini; Amy L McGuire; Mary A Majumder
Journal:  Science       Date:  2017-05-12       Impact factor: 47.728
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.